10:12 AM EDT, 07/22/2024 (MT Newswires) -- TC BioPharm ( TCBP ) said Monday it dosed the sixth patient in a trial of TCB-008, a potential treatment for acute myeloid leukemia.

The patient got a higher dose after an amendment approved by the UK's Medicines and Healthcare products Regulatory Agency in February, the company said.

Five people treated in a "safety" group showed no drug-related serious adverse events, TC BioPharm ( TCBP ) said.

Enrolled patients will get an increased dose with up to 230 million cells per dose, up from 35 million, the company said.